Es wurden 41 Produkte zu dem Suchbegriff hyperthermie in 5 Shops gefunden:

MOSQUITO heat it® Lightning Insekten-Stichheiler Der MOSQUITO heat it® Insekten-Stichheiler ist ein kompaktes Gerät zur Linderung von Juckreiz und Schmerzen nach Insektenstichen oder -bissen. Es nutzt die lokale Hyperthermie-Technologie, um betroffene Hautstellen auf etwa 50 °C zu erwärmen und dadurch Symptome schnell und effektiv zu lindern. Das Gerät ist speziell für iPhones mit Lightning-Anschluss (ab iPhone 6) entwickelt und lässt sich bequem über die kostenlose heat it® App steuern. 12 Behandlungsmodi, inklusive Kindermodus Chemikalienfreie Linderung durch Wärme Kompakt, leicht und am Schlüsselbund tragbar Kompatibel mit iPhones (iPhone 6-14) über Lightning-Anschluss Anwendung: Die heat it® App aus dem App-Store herunterladen und installieren. Den Stichheiler in den Lightning-Anschluss des Smartphones stecken. Die App öffnet sich automatisch und führt den Nutzer durch die Behandlung. Die betroffene Hautstelle für ein paar Sekunden erhitzen, um den Juckreiz und die Schmerzen zu lindern. Hersteller: Kamedi GmbH Haid-und-Neu-Straße 7 76131 Karlsruhe Deutschland

There is currently no description available

There is currently no description available

Hyperthermia as a tool for the treatment of malignant disease is rapidly becoming a clinical reality. In this book I am attempting to summarize the known biological and physical underpinnings that have led to this development. I also present a compilation of existing clinical results, limited as these are. My aim is to provide oncologists and other physicians with up-to-date information on this modality, which is both new and old, as well as to make available to biologists, physicists and engineers sum­ maries of currently available information on specific areas of hyperthermic research. Many people have helped me with this book. Specifically, thanks are due to Drs. William Dewey, Jean Dutreix, Peter Fessenden, Gloria Li, and Jane Marmor. Their suggestions have been invaluable. I hope that not too many errors and omissions have crept into the volume, but in any case, for these I have only myself to blame. I also wish to express my appreciation to David Betten and Marie Graham for their help. Most of this material was written while I was on sabbatical leave on the shores of Lake Atitlan in Guatemala. There I enjoyed the hospitality of a gracious, friendly, and proud people who deserve better than fate seems to have in store for them.

A HISTORY OF MALIGNANT HYPERTHERMIA Malignant hyperthermia (MH) is a hereditary disorder of muscle. Undoubtedly, individuals have possessed this trait since time immemorial. However, because the trait is usually only unmasked in the presence of potent inhalational anaesthetic agents or non-depolarizing skeletal muscle relaxants, the existence of malignant hyperthermia was not suspected until we" after the dawn of the modern anaesthetic era. In the early years of ether and chloroform anaesthesia, monitoring was minimal. Body temperature was never measured. A finger on the pulse, and observation of respirations and skin colour were the most that could be expected. Death was not infrequent and usually unexplained (1). By the beginning of the twentieth century, reports of fulminant fever and tachycardia (rapid heart rate) during or immediately after anaesthesia often ending in death, were being described with increasing frequency in the medical literature (2-6). As a number of cases from New York had occurred during summer months, they were initially thought to be a form of heat stroke due to overly hot operating theatres (2-6). However, one enterprising anaesthetist (5:' checked the weather reports for the days on which some of these so called "heat strokes" had occurred. He found that on the days i'n question the ambient 0 temperature had never been in excess of 72 F. Environmental heat, therefore, could not have been a cause of at least some of these reactions.

A HISTORY OF MALIGNANT HYPERTHERMIA Malignant hyperthermia (MH) is a hereditary disorder of muscle. Undoubtedly, individuals have possessed this trait since time immemorial. However, because the trait is usually only unmasked in the presence of potent inhalational anaesthetic agents or non-depolarizing skeletal muscle relaxants, the existence of malignant hyperthermia was not suspected until we" after the dawn of the modern anaesthetic era. In the early years of ether and chloroform anaesthesia, monitoring was minimal. Body temperature was never measured. A finger on the pulse, and observation of respirations and skin colour were the most that could be expected. Death was not infrequent and usually unexplained (1). By the beginning of the twentieth century, reports of fulminant fever and tachycardia (rapid heart rate) during or immediately after anaesthesia often ending in death, were being described with increasing frequency in the medical literature (2-6). As a number of cases from New York had occurred during summer months, they were initially thought to be a form of heat stroke due to overly hot operating theatres (2-6). However, one enterprising anaesthetist (5:' checked the weather reports for the days on which some of these so called "heat strokes" had occurred. He found that on the days i'n question the ambient 0 temperature had never been in excess of 72 F. Environmental heat, therefore, could not have been a cause of at least some of these reactions.

In susceptible individuals, malignant hyperthermia (MH) can be triggered by various anesthetics during surgery. First described in 1960, research since then has concentrated on reducing the very high mortality rate associated with MH. Although significant progress in treatment has been made with the introduction of dantrolene sodium in 1979, many questions remain unanswered. Following on the results of more than 30 years of investigative efforts, the Third International Symposium on MH was held in Hiroshima, Japan, in 1994, immediately before the Seventh International Workshop on MH. Specialists in the field discussed the most up-to-date findings from the point of view of clinical classification, history, and incidence based on the evidence of epidemiology, diagnostic muscle testing, genetics, and biochemistry. These proceedings of the symposium present important keys to understanding the mechanism of MH and related syndromes at the genetic level and include procedures for the monitoring and care of patients. This volume will be invaluable not only for surgeons and anesthesiologists but also for physiologists and researchers.

Hyperthermia as a safe and effective cancer treatment modality is rapidly evolving propelled by widespread research and clinical efforts worldwide. Presentations on Hyperthermia experience are now commonplace at Oncology meetings, as are congresses dedicated entirely to the intertwined interactions between basic sciences and patient treatment that together are forming the structure of a new medical specialty. Such was the XII International Symposium on Clinical Hyperthermia held in Rome, Italy, April 27 - 29, 1989. Papers presented therein constitute the backbone of this book. Biology research has provided data describing mechanisms of action for the cancer cell killing and physiological effects of Hyperthermia. Physics research has led to the development of equipment enabling treatment of many areas of the human body, as well as explained the limitations that still constrain our ability to treat, especially in the areas of deep seated tumor heating and non-invasive thermometry. The main question that will decide the future of this modality is that of its clinical use. To put it succinctly, what do we do with this potentially useful tool in an everyday clinical oncological practice . •• ? This is the main question addressed in this book as "Consensus on Hyperthermia for the 1990s. " The book in­ cludes 28 presented papers and 25 invited chapters from some of the leading experts in the field. Their basic mechanisms of action were physics principles, treatment quality assurance and especially, clinical indications.

Hyperthermia as a safe and effective cancer treatment modality is rapidly evolving propelled by widespread research and clinical efforts worldwide. Presentations on Hyperthermia experience are now commonplace at Oncology meetings, as are congresses dedicated entirely to the intertwined interactions between basic sciences and patient treatment that together are forming the structure of a new medical specialty. Such was the XII International Symposium on Clinical Hyperthermia held in Rome, Italy, April 27 - 29, 1989. Papers presented therein constitute the backbone of this book. Biology research has provided data describing mechanisms of action for the cancer cell killing and physiological effects of Hyperthermia. Physics research has led to the development of equipment enabling treatment of many areas of the human body, as well as explained the limitations that still constrain our ability to treat, especially in the areas of deep seated tumor heating and non-invasive thermometry. The main question that will decide the future of this modality is that of its clinical use. To put it succinctly, what do we do with this potentially useful tool in an everyday clinical oncological practice . •• ? This is the main question addressed in this book as "Consensus on Hyperthermia for the 1990s. " The book in­ cludes 28 presented papers and 25 invited chapters from some of the leading experts in the field. Their basic mechanisms of action were physics principles, treatment quality assurance and especially, clinical indications.

In susceptible individuals, malignant hyperthermia (MH) can be triggered by various anesthetics during surgery. First described in 1960, research since then has concentrated on reducing the very high mortality rate associated with MH. Although significant progress in treatment has been made with the introduction of dantrolene sodium in 1979, many questions remain unanswered. Following on the results of more than 30 years of investigative efforts, the Third International Symposium on MH was held in Hiroshima, Japan, in 1994, immediately before the Seventh International Workshop on MH. Specialists in the field discussed the most up-to-date findings from the point of view of clinical classification, history, and incidence based on the evidence of epidemiology, diagnostic muscle testing, genetics, and biochemistry. These proceedings of the symposium present important keys to understanding the mechanism of MH and related syndromes at the genetic level and include procedures for the monitoring and care of patients. This volume will be invaluable not only for surgeons and anesthesiologists but also for physiologists and researchers.

There is currently no description available

Following an introductory overview, Hyperthermia In Cancer Treatment: A Primer comprehensively describes the biological reasons for associating hyperthermia with radiation and chemotherapy and the biological and clinical effects of hyperthermia on cancerous and normal tissues. The volume’s 20 chapters are arranged in three principal parts: physical and methodological studies, biologic principles, and clinical studies.

Following an introductory overview, Hyperthermia In Cancer Treatment: A Primer comprehensively describes the biological reasons for associating hyperthermia with radiation and chemotherapy and the biological and clinical effects of hyperthermia on cancerous and normal tissues. The volume’s 20 chapters are arranged in three principal parts: physical and methodological studies, biologic principles, and clinical studies.

There is currently no description available

Malignant hyperthermia is a genetic disease that causes an extremely high body temperature. The syndrome is triggered by depolarizing muscle relaxants and halogenated gaseous anesthetics, such as halothane. The purpose of the book is to present the latest experimental work and important conclusions to anesthesiologists, surgeons, certified registered nurse anesthesists, operating nurses, cardiovascular and temperature oriented physiologists, basic research scientists interested in heat production in muscle, animal scientists, primarily swine physiologists, and finally, muscle biology scientists. The results are based on sixteen years of experimental investigations with a malignant hyperthermia susceptible pig colony. Consequently, the data and conclusions are more concrete than the clinical data from human patients. The first five chapters present fresh material relating to the detailed biochemical mechanism of heat production during malignant hyperthermia. Subsequent chapters present recent data on malignant hyperthermia in horses and dogs; these additional animal models provide useful material for future studies of malignant hyperthermia pathophysiology. Later sections summarize the laboratory methods currently used for diagnosing malignant hyperthermia in human patients and present valuable data on malignant hyperthermia in the greater Kansas city area over a twenty year period.

In the 1960s a firm rationale was developed for using raised temperatures to treat malignant disease and there has been a continuous expansion of the field ever since. However, a major limitation exists in our ability to heat human tumours, especially those sited deep in the body, with a reasonable degree of temperature uniformity. This problem has resulted in engineers and physicists collaborating closely with biologists and clinicians towards the common goal of developing and testing the clinical potential of this exciting treatment modality. The aim of the physicist and engineer is to develop acceptible methods of heating tumQur masses in as many sites as possible to therapeutic temperatures avoiding excessive heating of normal structures and, at the same time, obtaining the temperature distribution throughout the heated volume. The problem is magnified by both the theoretical and technical limitations of heating methods and devices. Moreover, the modelling of external deposition of energy in tissue and knowledge of tissue perfusion are ill-defined. To this must be added the conceptual difficulty of defining a thermal dose. The NATO course was designed to provide a basis for the integration of physics and technology relevant to the development of hyperthermia. There were 48 lectures covering the theoretical and practical aspects of system design and assessment, including, as far as possible, all the techniques of current interest and importance in the field.

Produktdetails: Art Bedienung: App-Bedienung, Drucktasten, Funktionen: Raumklimasteuerung, Ausstattung: Einzelraumregelung, LCD-Display, Temperaturmessung, Kompatible Smart-Home-Systeme: Homematic IP, Geeignet für: alle handelsüblichen Ventile, Art Befestigung: schrauben, Maße & Gewicht: Breite: 1,5 cm, Tiefe: 12,5 cm, Höhe: 10 cm, Gewicht: 0,34 kg, Farbe & Material: Farbbezeichnung: Weiß, Technische Daten: Signalübertragung: Funk, WEEE-Reg.-Nr. DE: 21.152.690, Stromversorgung: Art Stromversorgung: Batteriebetrieb, Batterie-/Akku-Technologie: 1,5-V-Mignon (LR6/AA), Anzahl Batterien: 2 Stk., Spannung Akku: 1,5 V, Lieferzustand Batterien / Akkus: Batterien beigelegt, Lieferung & Montage: Lieferumfang: Homematic IP Heizkörperthermostat – flex, Adapter Danfoss (RA, RAV und RAVL), Stützring und Montagematerial, 1,5 V LR6/Mignon/AA Batterien (2x), Bedienungsanleitung

Produktdetails: Art Bedienung: App-Bedienung, Funktionen: Raumklimasteuerung, Temperaturregelung, individuell programmierbar, Ausstattung: Einzelraumregelung, Temperaturmessung, Zeitschaltuhr, Anzahl Heizkörperthermostate: 2, Kompatible Smart-Home-Systeme: Homematic IP, Geeignet für: alle handelsüblichen Ventile, Art Befestigung: schrauben, Maße & Gewicht: Breite: 19,5 cm, Tiefe: 29,5 cm, Höhe: 10,5 cm, Gewicht: 0,5 kg, Farbe & Material: Farbbezeichnung: Weiß, Material Schraubring: Metall, Technische Daten: Betriebsart: elektronisch, Gewindeanschluss: M30 x 1,5 mm, Schutzart: IP20, Signalübertragung: Funk, Funkfrequenz: 868 MHz, Reichweite: 300 m, Displaytechnologie: LCD-Display, WEEE-Reg.-Nr. DE: 21.152.690, Stromversorgung: Art Stromversorgung: Batteriebetrieb, Anzahl Batterien: 4 Stk., Lieferung & Montage: Lieferumfang: 2x Homematic IP Heizkörperthermostat, 2x Adapter Danfoss (RA, RAV und RAVL), 2x Stößelverlängerung Danfoss RAV, 2x Stützring, 2x Zylinderkopfschraube M4 x 12 mm und Mutter M4, 2x 1,5 V LR6/Mignon/AA Batterien (2x), 2x Bedienungsanleitung

Produktdetails: Art Bedienung: App-Bedienung, Drehregler, Funktionen: Boost-Funktion für schnelleres Aufheizen, Raumklimasteuerung, Smart-Home-Steuerung, automatische Temperaturabsenkung beim Lüften, Ausstattung: Einzelraumregelung, Temperaturmessung, Kompatible Smart-Home-Systeme: Homematic IP, Geeignet für: alle handelsüblichen Ventile, Art Befestigung: schrauben, Set beinhaltet: 3x Heizkörperthermostat, Maße & Gewicht: Breite: 31 cm, Tiefe: 37 cm, Höhe: 12 cm, Gewicht: 1 kg, Farbe & Material: Farbbezeichnung: Weiß, Material Schraubring: Metall, Technische Daten: Betriebsart: elektronisch, Gewindeanschluss: M30 x 1,5 mm, Schutzart: IP20, Signalübertragung: Funk, Funkfrequenz: 868 MHz, Reichweite: 300 m, Displaytechnologie: LCD-Display, WEEE-Reg.-Nr. DE: 21.152.690, Stromversorgung: Art Stromversorgung: Batteriebetrieb, Batterie-/Akku-Technologie: 1,5-V-Mignon (LR6/AA), Anzahl Batterien: 6 Stk., Spannung Akku: 1,5 V, Lieferzustand Batterien / Akkus: Batterien beigelegt, Lieferung & Montage: Lieferumfang: 3x Homematic IP Heizkörperthermostat, 3x Adapter Danfoss (RA, RAV und RAVL), 3x Stößelverlängerung Danfoss RAV, 3x Stützring, 3x Zylinderkopfschraube M4 x 12 mm und Mutter M4, 3x 1,5 V LR6/Mignon/AA Batterien (2x), 3x Bedienungsanleitung, Batterien, Adapter, 3x Adapter Danfoss (RA,RAV und RAVL), Hinweise: Sprachen Bedienungs-/Aufbauanleitung: Deutsch (DE)

Steuere deine Raumtemperatur ganz bequem über die App, deine Stimme, das integrierte Touch-Bedienfeld oder tageszeit- und anwesenheitsabhängig. Wann immer du kommst und gehst, Eve Thermo regelt deine Heizung passend dazu: Energie sparend, wenn du unterwegs bist. Behaglich warm, wenn du es dir zu Hause gemütlich machst., Produktdetails: Art Bedienung: App-Bedienung, Anzahl Heizkörperthermostate: 2, Art Befestigung: schrauben, Farbe & Material: Farbbezeichnung: weiß, Material: Kunststoff, Technische Daten: Betriebsart: elektronisch, Signalübertragung: WLAN (Wi-Fi), WEEE-Reg.-Nr. DE: 84.385.528, Stromversorgung: Batterie-/Akku-Technologie: 1,2-V-Mignon (HR6/AA), Anzahl Batterien: 2 Stk., Lieferzustand Batterien / Akkus: Batterien beigelegt, Lieferung & Montage: Lieferumfang: 2x austauschbare AA Batterien, Montage-schraube, Hinweise: Sprachen Bedienungs-/Aufbauanleitung: Deutsch (DE)